The late-stage gene therapy pipeline is rapidly evolving, with five FDA approvals in the past year and several more BLA filings expected by 2024. As momentum builds towards significantly higher numbers of active later-stage clinical trials, the importance of comparability for drug developers and regulators is increasing.

That’s why the 4^th Gene Therapy Comparability Summit will be back in February 2024, hot on the heels of 2023 approvals, this summit will ensure that you can establish comparability in your clinical phase of development and prove to regulators that your products are comparable when scaling up for commercialization and navigating process changes.

Join us in February to design and implement an effective comparability study, significantly de-risk costly delays to clinical programs and ultimately increase the chances of approval.